Search by Abstract Number Results

Abstract Number: 827 • 2019 ACR/ARP Annual Meeting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia (FM): Evidence for a Broad Spectrum of Activity on the FM Syndrome
Gregory Sullivan¹, R. Michael Gendreau ², Judith Gendreau ³, Ashild Peters ⁴, Perry Peters ⁵ and Seth Lederman ⁶, ¹Tonix Pharmaceuticals Inc., New York, ²Gendreau Consulting, Poway, CA, ³Tonix Pharmaceuticals Inc, Poway, CA, ⁴Tonix Pharmaceuticals Inc., San Diego, CA, ⁵Tonix Pharmaceuticals Inc, San Diego, CA, ⁶Tonix Pharmaceuticals Inc, New York, NY
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain, unrefreshing sleep, fatigue, and cognitive complaints. TNX-102 SL* is a sublingual (SL) formulation of cyclobenzaprine (CBP)…
Abstract Number: 827 • 2018 ACR/ARHP Annual Meeting
Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes and Adverse Events
Caitrin Coffey¹, Michael Richter¹, Cynthia S. Crowson², Matthew J. Koster³, Kenneth J. Warrington⁴ and Ashima Makol³, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Rheumatoid vasculitis (RV) is a rare systemic inflammatory process affecting small to medium sized blood vessels in patients with rheumatoid arthritis (RA). RV confers…
Abstract Number: 827 • 2017 ACR/ARHP Annual Meeting
Temporary Methotrexate Discontinuation for 2 Weeks Improves Immunogenicity of Seasonal Influenza Vaccination in Patients with Rheumatoid Arthritis: A Randomized Clinical Trial
Jin Kyun Park¹, Kichul Shin², You-Jung Ha³, Yun Jong Lee⁴, Eun Young Lee⁵, Yeong Wook Song⁶, Yunhee Choi⁷, Kevin Winthrop⁸ and Eun Bong Lee⁹, ¹Division of Rheumatology, Seoul National University Hospital, Seoul, Korea, Republic of (South), ²Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ³Yonsei University College of Medicine, Seoul, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, Korea, Republic of (South), ⁶Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, The Republic of, Seoul, Korea, Republic of (South), ⁷Division of Medical Statistics, Medical Research Collaborating Center, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁸Oregon Health & Science University, Portland, OR, ⁹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Methotrexate (MTX), a widely used immune-suppressive agent, decreases vaccine response in patients with rheumatoid arthritis (RA). We investigated whether a temporary MTX discontinuation for…
Abstract Number: 827 • 2016 ACR/ARHP Annual Meeting
Severe Gastrointestinal Disease in Early Systemic Sclerosis Is Associated with an Increased Risk of Mortality
Nicolas Richard¹, Marie Hudson², Mianbo Wang³, Murray Baron⁴, Genevieve Gyger¹ and Canadian Scleroderma Research Group, ¹McGill University, Jewish General Hospital, Montreal, QC, Canada, ²Medicine/Rheumatology, Jewish General Hospital, Lady Davis Research Institute, Montreal, QC, Canada, ³Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁴Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Studies of severe gastrointestinal (GI) disease in systemic sclerosis (SSc) are limited by small, selected samples composed largely of subjects with prevalent disease. We…
Abstract Number: 827 • 2015 ACR/ARHP Annual Meeting
Reliability of the Quantitative Assessment of Peripheral Blood Perfusion By Laser Speckle Contrast Analysis in a Systemic Sclerosis Cohort
Valérie Lambrecht¹, Maurizio Cutolo², Filip De Keyser³, Saskia Decuman⁴, Barbara Ruaro², Alberto Sulli⁵, Ellen Deschepper⁶ and Vanessa Smith⁷, ¹Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ³Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁴Department of Rheumatology, UGent, Ghent, Belgium, ⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, Genova, Italy, ⁶Biostatistics Unit, Biostatistics Unit, Ghent University, Ghent, Belgium, ⁷Department of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium
Background/Purpose: Laser speckle contrast analysis (LASCA) is an innovative technique to quantify peripheral blood perfusion (PBP) over a given area. Quantification of blood flow might…
Abstract Number: 827 • 2014 ACR/ARHP Annual Meeting
Gout and the Risk of Alzheimer’s Disease: A Population-Based Cohort Study
Na Lu¹, Yuqing Zhang¹, Alberto Ascherio², Miguel Hernan², Tuhina Neogi¹, Maureen Dubreuil^3,4 and Hyon K. Choi⁵, ¹Boston University School of Medicine, Boston, MA, ²Epidemiology, Harvard School of Public Health, Boston, MA, ³Rheumatology, Boston University Medical Center, Boston, MA, ⁴Rheumatology, Boston VA HealthCare System, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: While gout is associated with cardiovascular (CV)-metabolic comorbidities and their sequelae, uric acid's anti-oxidant effects may have neuroprotective benefits. Several studies have found an…
Abstract Number: 827 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness and Cost-Utility Of a One-Year Coaching Program For Healthy Physical Activity In Rheumatoid Arthritis
Nina Brodin^1,2, Malin Lohela Karlsson³, Emma Swärdh² and Christina H. Opava⁴, ¹Department of Orthopaedics, Division of Physiotherapy, Dandeyd Hospital, Stockholm, Sweden, ²Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet, SE 14183 Huddinge, Sweden, ³Institute of Environmental Medicine (IMM), Intervention and Implementation Research Unit, Karolinska Institutet, Stockholm, Sweden, ⁴Neurobiology, Care Sciences and Society, Division of Physical Therapy, Karolinska Institutet, Huddinge, Sweden
Background/Purpose: Economic evaluations of interventions, as a complement to the effect evaluation, intend to inform decision makers about whether an intervention provides good value for…
Abstract Number: 827 • 2012 ACR/ARHP Annual Meeting
Sustained Development of Cardiovascular Disease in Rheumatoid Arthritis Despite Cardioprotective Treatment: The 10-Year Prospective Carre-Study
Alper M. van Sijl¹, Inge A.M. van den Oever¹, Mike J.L. Peters², Vokko P. van Halm³, Alexandre E. Voskuyl⁴, Yvo M. Smulders⁵ and Mike T. Nurmohamed¹, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Internal medicine, VU University Medical Center, Amsterdam, Netherlands, ³Cardiology, Academic Medical Centre, Amsterdam, Netherlands, ⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Internal Medicine, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease which is associated with an increased cardiovascular (CV) risk. It is still unknown to what…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].